<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02256852</url>
  </required_header>
  <id_info>
    <org_study_id>QBKPN-01</org_study_id>
    <nct_id>NCT02256852</nct_id>
  </id_info>
  <brief_title>Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer</brief_title>
  <official_title>Open Label,Single Arm,Exploratory Study to Evaluate the Safety,Tolerability,Compliance and MOA,of QBKPN SSI in Subjects With 2 or More Second Primary Pre-invasive/Invasive Adenocarcinoma Following Surgical Resection of Stage I NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qu Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qu Biologics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, compliance and mechanism
      of action of study drug (QBKPN SSI) in subjects with two or more second primary pre-invasive
      or invasive adenocarcinoma following surgical section of Stage 1 NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please refer to summary above.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, tolerability and compliance variables</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assess the number of adverse events and subject reported data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploratory variables</measure>
    <time_frame>16 weeks</time_frame>
    <description>Assess and identify biomarkers associated with immune response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>QBKPN SSI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualized maintenance dose administered subcutaneously for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>QBKPN SSI</intervention_name>
    <description>QBKPN SSI is administered subcutaneously for 12 weeks</description>
    <arm_group_label>QBKPN SSI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female who is at or above the age of consent

          -  Histologically confirmed original diagnosis of lung cancer

          -  Life expectancy greater than 12 months

          -  ECOG performance status 0, 1, or 2 at screening

          -  Female subjects who agree to practice two effective methods of contraception from the
             time of signing the informed consent form through one month after the last dose of
             study drug

          -  Male subjects who agree to practice effective barrier contraception during the entire
             study drug period and through one month after the last dose of study drug

        Exclusion Criteria:

          -  Extra-thoracic lung cancer progression

          -  Any active malignancies

          -  Any uncontrolled or major organ dysfunction

          -  Any past or current radiation or systemic therapies for the treatment of lung cancer

          -  Known HIV infection or other immunosuppressive disorder

          -  Concurrently participating in another study with an investigational immunotherapy or
             have received investigational immunotherapy within 3 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Stephen Lam</last_name>
    <role>Principal Investigator</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BC Cancer Research Centre</name>
      <address>
        <city>Vancouver</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2014</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

